MMJ Group Holdings Ltd

MMJ Group expands into EU by investing in leading Polish cannabis extraction company

Settlement of the Sequoya investment is expected before August 31, 2019, and will be funded from the company’s existing cash reserves of A$25 million.

1563774787_shutterstock_734579047.jpg
MMJ Group manages a portfolio of investments along the cannabis value-chain

MMJ Group Holdings Limited (ASX:MMJ) (FRA:2P9) (OTCMKTS:MMJJF) is entering the lucrative European Union, which has a large and growing medicinal cannabis market, by investing C$2.5 million in privately-held Polish cannabis extraction company Sequoya Cannabis Limited.

The company worked with its specialist management company Embark Ventures to structure the transaction, with Sequoya being the second investment originated for MMJ.

This investment forms part of MMJ Group's strategy of managing a portfolio of investments along the cannabis value-chain.

READ: MMJ books 33% investment return for FY2019

MMJ Group chairman Peter Wall said: “This is another example of MMJ’s strong market and financial discipline identifying opportunities and bottlenecks in the cannabis value-chain in markets and acting quickly."

Wall said: “The investment demonstrates MMJ’s capacity to secure investment in private cannabis businesses which are not generally available to Australian retail and institutional investors.”

Sequoya’s immediate focus is to become a substantial GMP certified hemp cannabidiol (CBD) supplier, with longer term plans to expand into the legal medical marijuana market across Europe.

Its cannabis extraction operations will be established in Krakow, Poland, with plans to become a leading supplier of CBD extracts and isolate within the European Union.

CBD production from hemp is legal across Europe with no cross-border tariffs within the European Union.

Additionally, no specific permits are required for producing hemp-derived CBD in Poland.

READ: MMJ Group leveraged to Hemple hemp and cannabinoid brand in US

Sequoya is also focusing on extraction which is the highest value opportunity within the cannabis ecosystem, and it is building a large-scale production plant in a low-cost jurisdiction which has easy no-tariff access to high value markets such as Germany and northern Europe.

MMJ’s investment consists of a C$2.5 million convertible note issued by the Canadian holding company, which may be converted into about 34% of Sequoya’s issued capital within two years.

This investment will be held through wholly-owned subsidiary Phytotech Medical (UK) Pty Ltd.  

The company has secured the rights to make further investments in Sequoya through:

  • Warrants that allow MMJ to acquire further shares following the conversion of the debenture for a period of two years following the date of issue; and
  • An option to invest a further C$2.5 million to finance the next stage of Sequoya’s business plan.

Quick facts: MMJ Group Holdings Ltd

Price: $0.25

Market: ASX
Market Cap: $56.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MMJ Group Holdings Ltd named herein, including the promotion by the Company of MMJ Group Holdings Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MMJ Group focuses on strategic vision to be leading cannabis investment company

MMJ Group Holdings Ltd (ASX: MMJ) non-executive director Mike Curtis updates Proactive Investors about its strategic partnership with MMJ operating company Embark Ventures (EBV). The two companies have combined to create the highest quality investments, earnings and share price return for...

on 17/7/19

3 min read